Funds · compare two funds
Are these two funds really different?
Pick two funds to see how much of their Indian equity is the same: the companies both hold, and what each holds that the other does not.
Data periodFund holdingsEach fund’s latest monthly disclosureNSE prices23 Oct 2026Data status →
NIPPON INDIA PHARMA FUND vs Mirae Asset Nifty 500 Healthcare ETF
Overlap adds up, for every company both funds hold, the smaller of its two shares of each fund’s disclosed Indian equity: identical portfolios overlap 100%, funds with nothing in common 0%. A figure describes how alike the portfolios are; it is not a judgement of either fund. Method →
See both funds combined in the Portfolio X-ray →
Top shared holdings
26 companies both funds hold · largest common part first
Only in A
10 companies · largest first
- Medplus Health Services Limited2.60%
- Thyrocare Technologies Limited2.30%
- Suraksha Diagnostic Limited1.55%
- Pfizer Limited1.38%
- Akums Drugs and Pharmaceuticals Limited1.24%
- Sanofi India Limited1.03%
- Sanofi Consumer Healthcare India Limited0.91%
- Molbio Diagnostics Limited0.56%
- Indoco Remedies Limited0.49%
- AstraZeneca Pharma India Limited0.43%
Only in B
18 companies · largest first
- Laurus Labs Limited5.72%
- Torrent Pharmaceuticals Limited5.24%
- Glenmark Pharmaceuticals Limited2.61%
- Zydus Lifesciences Limited2.14%
- Krishna Institute of Medical Sciences Limited1.48%
- Aster DM Quality Care Limited1.38%
- Neuland Laboratories Limited1.36%
- Wockhardt Limited1.30%
- Acutaas Chemicals Limited1.26%
- Granules India Limited0.93%
- Global Health Limited0.90%
- Onesource Specialty Pharma Limited0.89%
- Natco Pharma Limited0.55%
- Cohance Lifesciences Limited0.54%
- Rainbow Childrens Medicare Limited0.49%
And 3 more.
Sector mix side by side
Share of each fund’s disclosed equity
| Sector | A | B | Difference |
|---|---|---|---|
| Healthcare | 92.4% | 100.0% | -7.58 pp |
| Consumer Services | 2.6% | 0.0% | +2.60 pp |
| Not classified | 5.0% | 0.0% | +4.98 pp |
Built from each fund’s latest monthly disclosure of Indian listed shares, valued at official NSE closing prices. Cash, debt, derivatives and overseas holdings are not part of the comparison. Not a recommendation. Method →